Listen

Add to my selection

OFEV

Medicine - Posted on Feb 10 2023

Active substance (DCI)

nintédanib

history (4)

1/18/23

OFEV (nintedanib) - Pulmonary fibrosis

Reassessment. Key points Favourable opinion for maintenance of reimbursement in the idiopathic pulmonary fibrosis indication...

CAV :
54321

icône flèche
12/16/20

OFEV - PID-ScS chez l’adulte (nintedanib)

Key points Favourable opinion for reimbursement in the treatment of systemic sclerosis associated interstitial lung disease ...

CAV :
54321

icône flèche
12/16/20

OFEV - PID (nintedanib)

Key points Favourable opinion for reimbursement in the treatment of other chronic fibrosing interstitial lung diseases (ILDs...

CAV :
54321

icône flèche
5/20/15

OFEV (nintedanib), inhibitor of tyrosine kinases

Minor improvement in the treatment of idiopathic pulmonary fibrosis in patients with a predicted FVC ≥ 50% and a DLco ≥ 30%....

CAV :
54321

icône flèche

Technical information

ATC code

L01EX09

Manufacturer

BOEHRINGER INGELHEIM FRANCE

Presentation

OFEV 100 mg, capsule molle (code CIS : 62388307)
60 plaquette(s) thermoformée(s) aluminium de 1 comprimé(s) (CIP : 34009 300 060 2 3)

OFEV 150 mg, capsule molle (code CIS : 62960765)
60 plaquette(s) thermoformée(s) aluminium de 1 comprimé(s) (CIP : 34009 300 060 4 7)

All our publications

Congenital, genetic and rare diseases

Pulmonary and pleural diseases